Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
- PMID: 25004145
- PMCID: PMC4155856
- DOI: 10.1590/0074-0276130563
Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
Abstract
Antimony compounds are the cornerstone treatments for tegumentary leishmaniasis. The reactivation of herpes virus is a side effect described in few reports. We conducted an observational study to describe the incidence of herpes zoster reactivation during treatment with antimony compounds. The global incidence of herpes zoster is approximately 2.5 cases per 1,000 persons per month (or 30 cases per 1,000 persons per year). The estimated incidence of herpes zoster in patients undergoing antimony therapy is higher than previously reported.
Figures
References
-
- Aslamazov EG, Metel’skaia AO, Tumol’skaia NI. Herpes zoster as a result of the toxic effect of antimony compounds on the organism. Med Parazitol (Mosk) 1966;35:600–601. - PubMed
-
- Campbell K. Incidence rates and correlates of risk of herpes zoster, US Armed Forces, 1998-2001. MSMR. 2002;8:2–5.
-
- Chakravarty EF. Viral infection and reactivation in autoimmune disease. Arthritis Rheum. 2008;58:2949–2957. - PubMed
-
- Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JB, Chunge C, Beyceson AD. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis. 1983;148:148–155. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
